Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

被引：0
|
作者：
Janne, Pasi A.
Ramalingam, Suresh S.
Yang, James Chih-Hsin
Riely, Gregory J.
Bunn, Veronica
Jin, Shu
Zhou, Caicun
Camidge, D. Ross
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Emory Univ, Atlanta, GA USA
[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY USA
[5] Takeda Dev Ctr Americas Inc, Lexington, MA USA
[6] Shanghai Pulm Hosp, Shanghai, Peoples R China
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9099
引用
收藏
页数：1
相关论文
共 38 条
  • [31] Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison
    Ou, Sai -Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao M.
    Hong, Jin-liern
    Tan, Min
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti
    Nguyen, Danny
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2024, 25 (03) : e145 - e152.e3
  • [32] REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Wei, Ying Cheng Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Phase III study of zipalertinib plus fi rst-line (1L) platinum- based chemotherapy in patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations (REZILIENT3): Safety lead-in results
    Kurata, T.
    Fujiwara, Y.
    Naoki, K.
    Viteri, S.
    Inoue, T.
    Hangai, N.
    Wei, L.
    Kawabata, R.
    Wacheck, V.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2024, 35
  • [34] Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
    Girard, N.
    Park, K.
    Viteri, S.
    Schioppa, C. A.
    Diels, J.
    Oguz, M.
    Rodrigues, B. H.
    Rahhali, N.
    Sermon, J.
    Ghilotti, F.
    Li, T.
    Knoblauch, R. E.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S38
  • [35] Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm open-label, multicentre, phase 2 trial
    Wang, Mengzhao
    Fan, Yun
    Sun, Meili
    Wang, Yongsheng
    Zhao, Yanqiu
    Jin, Bo
    Hu, Ying
    Han, Zhigang
    Song, Xia
    Liu, Anwen
    Tang, Kejing
    Ding, Cuimin
    Liang, Li
    Wu, Lin
    Gao, Junzhen
    Wang, Jianghong
    Cheng, Ying
    Zhou, Jianying
    He, Yong
    Dong, Xiaorong
    Yao, Yu
    Yu, Yan
    Wang, Huijie
    Sun, Si
    Huang, Jianan
    Fang, Jian
    Li, Wen
    Wang, Lin
    Ren, Xiubao
    Zhou, Chengzhi
    Hu, Yanping
    Zhao, Dahai
    Yang, Runxiang
    Xu, Fei
    Huang, Yijiang
    Pan, Yueyin
    Cui, Jiuwei
    Xu, Yan
    Yang, Zhenfan
    Shi, Yuankai
    LANCET RESPIRATORY MEDICINE, 2024, 12 (03): : 217 - 224
  • [36] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Cheng, Ying
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
    Nishio, Makoto
    Yu, Helena Alexandra
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel Shao-Weng
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS219 - TPS219
  • [38] Positive CHMP Recommendation for RYBREVANT® (Amivantamab) for Treatment of adult Patients with advanced non-small cell Lung Cancer and activating EGFR Exon20 Insertion Mutations after Failure of platinum-based Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12)
1234